Asset
Sparsentan
Travere Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03762850 | phase3 | active_not_recruiting | 2018-12-11 | 2023-08-07 | Travere Therapeutics, Inc. | A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy |
| NCT05856760 | phase2 | completed | 2023-05-19 | 2024-10-14 | Travere Therapeutics, Inc. | A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN |
| NCT01613118 | phase2 | completed | 2014-03-01 | 2016-06-01 | Travere Therapeutics, Inc. | Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis |
| NCT07219121 | phase4 | active_not_recruiting | 2025-10-07 | 2027-03-01 | Travere Therapeutics, Inc. | Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis |
| NCT05003986 | phase2 | recruiting | 2021-08-12 | 2027-03-12 | Travere Therapeutics, Inc. | Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 216403 | NDA | TRAVERE THERAPEUTICS INC |
Marketed products (2)
- FILSPARI
- FILSPARI